Company Overview and News

 
China’s running craze could spawn sportswear unicorn, says Kappa’s owner

2018-05-13 scmp
Boss of China Dongxiang, which owns the iconic Italian brand in mainland China, predicts a US$1 billion domestic firm will emerge in the booming running sector

 
Here's Your 50 Top-Yield Consumer Cyclical Dividend Stocks For March (And Net Gains, Too)

2018-03-29 seekingalpha
China Dongxiang led Corus, Persimmon, New Media, and Greene King as top yield Consumer Cyclical sector favorites per dividend/price estimates calculated 3/27/18.

 
80 High-Yield 10%-Plus Dividend Leaders For April

2018-03-28 seekingalpha
80 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 3/26/18. Yields above 12.2% narrowed the list to 30 for comparison.

 
79 High Yield 10%+ Dividend Leaders Could Deliver Up To 39% By March 2019

2018-02-28 seekingalpha
79 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 2/26/18. Yields above 12.2% narrowed the list to 30 for comparison.

 
Tupperware, Ford And China Lead Consumer Cyclical Sector February Gains

2018-02-21 seekingalpha
Tupperware led Ford, China Dongxiang, Guess?, and L Brands as net gain Consumer Cyclical sector favorites per analyst target-price estimates calculated 2/16/18.

 
Tupperware, Ford & China Lead Consumer Cyclical Sector February Gains

2018-02-21 seekingalpha
Tupperware led Ford, China Dongxiang, Guess?, and L Brands as net gain Consumer Cyclical sector favorites per analyst target-price estimates calculated 2/16/18.

1
85 10%+ Yield Dividend Stocks: Stonemore, Uniti, American Shipping & China Dongxiang Top Broker Target Gains To February 2019

2018-01-29 seekingalpha
85 U.S. stocks displayed 10%+ forward yield, $2+ prices, and $100M+ market caps as of 1/26/18. Yields above 12.60% narrowed the list to 30 for comparison.

 
Salem Leads Consumer Cyclical Sector Top Gain Stocks For December Per Broker Targets

2017-12-26 seekingalpha
Salem Media led Corus Entertainment, GWA Group, and Gamehost as net gain Consumer Cyclical sector favorites per analyst target-price estimates calculated 12/22/17.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...